The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease

Canadian Journal of Gastroenterology

Volumn 20, Issue 4, 2006, Pages 277-280

  Zapata Colindres, Juan Carlos ^a   Zepeda Gómez, Sergio ^a   Montaño Loza, Aldo ^a   Vásquez Ballesteros, Edgar ^a   de Jesús Villalobos, José ^a   Valdovinos Andraca, Francisco ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Bleeding peptic ulcer; Helicobacter pylori; Nonsteroidal anti inflammatory drugs; Peptic ulcer disease

Indexed keywords

ANTIBIOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ENDOSCOPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; MEDICAL RECORD REVIEW; PATIENT CODING; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; STATISTICAL ANALYSIS;

EID: 33646384387     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/175217     Document Type: Article

References (25)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99. (Erratum 1999;341:548).
3. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984-91.
4. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994;35:742-5.
5. Moran AP, Wadstrom T. Pathogenesis of Helicobacter pylori. Curr Opin Gastroenterol 1998;14(Suppl):S9-14.
6. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years. Gastroenterology 1997;112:1000-16.
7. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
8. Dooley CP, Cohen H, Fitzgibbons PL, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989;321:1562-6.
9. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2037-46.
10. Barr M, Buckley M, O'Morain C. Review article: Non-steroidal anti-inflammatory drugs and Helicobacter pylori. Aliment Pharmacol Ther 2000;14(Suppl 3):43-7.
11. Ballesteros-Amozurrutia. [Peptic ulcer and Helicobacter pylori. Results and consequences of its eradication.] Rev Gastroenterol Mex 2000;65(Suppl 2):41-9.
12. Loeb DS, Talley NJ, Ahlquist DA, Carpenter HA, Zinsmeister AR. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: The role of Helicobacter pylori. Gastroenterology 1992;102:1899-905.
13. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 2002;359:14-22.
14. Aalykke C, Lauritsen J, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study. Gastroenterology 1999;116:1305-9.
15. Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal antiinflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 1992;87:1398-402.
16. Pilotto A, Leandro G, Di Mario F, Franceschi M, Bozzola L, Varerio G. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: A case-control study. Dig Dis Sci 1997;42:586-91.
17. Rodriguez-Hernandez H, Jacobo-Karam JS, Jaquez-Quintana JO, et al. [Gastropathy caused by non-steroidal anti-inflammatory agents and its association with Helicobacter pylori.] Rev Invest Clin 2003;55:254-9.
18. Santolaria S, Lanas A, Benito R, Perez-Aisa M, Montoro M, Sainz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999;13:1511-8.
19. Heresbach D, Raoul JL, Bretagne JF, et al. Helicobacter pylori: A risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy. Gut 1992;33:1608-11.
20. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
21. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: A randomized trial. Lancet 2002;359:9-13.
22. Hunt RH, Bazzoli F. Review article: Should NSAID/low-dose aspirin takers be tested routinely for H pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004;19(Suppl 1):9-16.
23. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998;352:1016-21. (Erratum 1998;352:1634).
24. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-8.
25. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002;16:167-80.